BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 31518151)

  • 1. Overall Shape Constraint of Alternating α/β-Hybrid Peptides Containing Bicyclic β-Proline.
    Wang S; Otani Y; Zhai L; Su A; Nara M; Kawahata M; Yamaguchi K; Sada A; Ohki R; Ohwada T
    Org Lett; 2019 Oct; 21(19):7813-7817. PubMed ID: 31518151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-naturally Occurring Helical Molecules Can Interfere with p53-MDM2 and p53-MDMX Protein-Protein Interactions.
    Su A; Wang S; Sada A; Otani Y; Zhai L; Liu X; Sayama M; Ohki R; Ohwada T
    Chem Pharm Bull (Tokyo); 2019; 67(10):1139-1143. PubMed ID: 31582633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
    Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Adaptation of Secondary p53 Binding Sites on MDM2 and MDMX.
    Higbee PS; Dayhoff GW; Anbanandam A; Varma S; Daughdrill G
    J Mol Biol; 2024 Jul; 436(13):168626. PubMed ID: 38810774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
    Chen J; Zhang D; Zhang Y; Li G
    Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein.
    Joseph TL; Lane D; Verma CS
    Cell Cycle; 2010 Nov; 9(22):4560-8. PubMed ID: 21088491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct observations of conformational distributions of intrinsically disordered p53 peptides using UV Raman and explicit solvent simulations.
    Xiong K; Zwier MC; Myshakina NS; Burger VM; Asher SA; Chong LT
    J Phys Chem A; 2011 Sep; 115(34):9520-7. PubMed ID: 21528875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of peptide retro-inverso isomerization in molecular mimicry.
    Li C; Pazgier M; Li J; Li C; Liu M; Zou G; Li Z; Chen J; Tarasov SG; Lu WY; Lu W
    J Biol Chem; 2010 Jun; 285(25):19572-81. PubMed ID: 20382735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations.
    Yadahalli S; Li J; Lane DP; Gosavi S; Verma CS
    Sci Rep; 2017 Nov; 7(1):15600. PubMed ID: 29142290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miniature protein inhibitors of the p53-hDM2 interaction.
    Kritzer JA; Zutshi R; Cheah M; Ran FA; Webman R; Wongjirad TM; Schepartz A
    Chembiochem; 2006 Jan; 7(1):29-31. PubMed ID: 16397877
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
    Lee XA; Verma C; Sim AYL
    Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.
    García-Echeverría C; Chène P; Blommers MJ; Furet P
    J Med Chem; 2000 Aug; 43(17):3205-8. PubMed ID: 10966738
    [No Abstract]   [Full Text] [Related]  

  • 17. Diarylethene moiety as an enthalpy-entropy switch: photoisomerizable stapled peptides for modulating p53/MDM2 interaction.
    Strizhak AV; Babii O; Afonin S; Bakanovich I; Pantelejevs T; Xu W; Fowler E; Eapen R; Sharma K; Platonov MO; Hurmach VV; Itzhaki L; Hyvönen M; Ulrich AS; Spring DR; Komarov IV
    Org Biomol Chem; 2020 Jul; 18(28):5359-5369. PubMed ID: 32390036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridged beta(3)-peptide inhibitors of p53-hDM2 complexation: correlation between affinity and cell permeability.
    Bautista AD; Appelbaum JS; Craig CJ; Michel J; Schepartz A
    J Am Chem Soc; 2010 Mar; 132(9):2904-6. PubMed ID: 20158215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
    Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
    Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.